

Glicturn M 60 - 500 Tablet

Brand Name: Glicturn M 60/500 Tablet

Dosage Form: Tablet

Composition:

Each tablet contains:

- Gliclazide Modified Release IP 60 mg
 - Metformin Hydrochloride IP 500 mg
-

Description:

Glicturn M 60/500 Tablet is a fixed-dose combination of Gliclazide Modified Release, a second-generation sulfonylurea, and Metformin Hydrochloride, a biguanide antihyperglycemic agent. It is indicated for the management of type 2 diabetes mellitus in adults whose blood glucose levels are inadequately controlled with diet, exercise, or monotherapy. The combination provides complementary mechanisms of action to improve insulin secretion, reduce hepatic glucose production, enhance peripheral insulin sensitivity, and achieve sustained glycemic control.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus in adults
- Patients inadequately controlled with Gliclazide or Metformin monotherapy
- Adjunct to diet and exercise for improved glycemic control
- Combination therapy to reduce fasting and postprandial blood glucose levels

It helps achieve effective long-term glycemic control and reduces the risk of diabetes-related complications.

Dosage & Administration:

Dosage should be individualized and administered as directed by the physician.

The tablet should preferably be taken with meals to minimize gastrointestinal side effects.

Swallow the modified release tablet whole with water. Do not crush, chew, or break the tablet.

Regular monitoring of blood glucose, HbA1c, renal function, and liver function is recommended during therapy.

Pharmacological Action:

- Gliclazide Modified Release stimulates insulin secretion from functional pancreatic β -cells by blocking ATP-sensitive potassium channels, leading to enhanced insulin release and improved glycemic control.
- Metformin Hydrochloride decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity without stimulating insulin secretion.
- The modified release formulation of Gliclazide provides sustained drug release, ensuring prolonged glycemic control with reduced fluctuations in plasma drug concentrations.

Together, these complementary mechanisms effectively control blood glucose levels in patients with type 2 diabetes mellitus.

Side Effects:

Common side effects include hypoglycemia, nausea, vomiting, diarrhea, abdominal discomfort, metallic taste, headache, dizziness, and weight gain.

Rarely, lactic acidosis, vitamin B12 deficiency, hypersensitivity reactions, hepatic dysfunction, or hematological disorders may occur.

Precautions & Warnings:

- Monitor blood glucose, HbA1c, renal function, and liver function periodically.
 - Educate patients regarding the recognition and management of hypoglycemia.
 - Use with caution in patients with renal impairment, hepatic impairment, or conditions predisposing to lactic acidosis.
 - Avoid excessive alcohol consumption during therapy.
 - Temporarily discontinue Metformin before iodinated contrast imaging procedures or major surgery, as advised by the physician.
 - Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
-

Drug Interactions:

May interact with insulin, other oral antidiabetic agents, corticosteroids, thiazide diuretics, beta-blockers, ACE inhibitors, NSAIDs, alcohol, iodinated contrast media, rifampicin, and fluconazole. Dose adjustment and close clinical monitoring may be required during concomitant therapy.

Storage:

Store below 25°C in a cool, dry place.
Protect from light and moisture.
Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113

Corporate Office :

Plot no. 307, Industrial Area Phase-2,
Panchkula, Haryana -134113

TM: Trademark Applied for